Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late
Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and management and attracted new institutional and impact investors including a cornerstone
Carina Biotech has entered a collaboration agreement with Melbourne biotech AdAlta to develop precision engineered, i-body enabled CAR-T therapies that provide new hope for patients with cancer. To learn more, watch
We are very pleased to welcome to our corporate team Jade Foeng, researcher & PhD student in Professor Shaun McColl's lab at University of Adelaide. Jade, a researcher with Carina for 3+
Carina Biotech's four-member Medical Advisory Board will advise us as we prepare to take our LGR5-targeted CAR-T cell for advanced colorectal cancer into the clinic over the next 12-18 months.
Emma Thompson is a PhD candidate in Professor Claudine Bonder's Vascular Biology & Cell Trafficking Laboratory at UniSA's Centre for Cancer Biology. Emma's research is focused on testing Carina Biotech's LGR5-targeting CAR-T
Story by Hayden Smith, featured in The Weekend Australian, 5 June 2021 Battling blood cancer in my 20s, I put my faith in a clinical trial for a promising new
Colorectal cancer, also known as bowel cancer, colon cancer or rectal cancer, affects men and women, young and old. Australia has one of the highest rates of colorectal cancer in
Carina Biotech has welcomed to its team two new staff members – Professor Shaun McColl and Dr José Iglesias MD. These two experts in immunology, T cell biology, oncology and
Dr Deborah Rathjen After completing its first (and second) commercial deals in the middle of last year, Carina is now rapidly transitioning from CAR-T discovery company to an emerging clinical
